The Cancer Letter

Inside information on cancer research and drug development

Vol.
44
No.
30
July 27, 2018Jul 27, 2018
Free
DOWNLOAD THE PDF
New drugs and new ideas are transforming AML
Cover Story
Free

New drugs and new ideas

are transforming AML
By Paul Goldberg
An actuary might note that if you were in residency at the time when the 7+3 protocol of cytarabine and daunorubicin was first used to treat acute myelogenous leukemia, chances are you are considering retirement just about now.
OSU's Byrd: “It's becoming necessary to consult with an expert, because it is complicated, and things are moving”
Conversation with The Cancer LetterFree
By Paul Goldberg
Agios's Schenkein: “It's not one disease. Just like lung cancer's not one disease”
Conversation with The Cancer LetterFree
By Paul Goldberg
FDA will organize new review divisions around disease types, Gottlieb testifies
Free
By Jordan Williams and Matthew Bin Han Ong

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account